Caxton Associates (New York)’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-10,640
| Closed | -$192K | – | 672 |
|
|
2024
Q3 | $192K | Sell |
10,640
-19,067
| -64% | -$344K | 0.01% | 488 |
|
|
2024
Q2 | $483K | Buy |
+29,707
| New | +$483K | 0.02% | 345 |
|
|
2022
Q4 | – | Sell |
-60,525
| Closed | -$488K | – | 584 |
|
|
2022
Q3 | $488K | Buy |
60,525
+42,691
| +239% | +$344K | 0.07% | 227 |
|
|
2022
Q2 | $134K | Buy |
+17,834
| New | +$134K | 0.01% | 482 |
|
|
2018
Q2 | – | Sell |
-54,000
| Closed | -$923K | – | 430 |
|
|
2018
Q1 | $923K | Buy |
+54,000
| New | +$923K | 0.05% | 153 |
|
|
2017
Q4 | – | Sell |
-13,300
| Closed | -$234K | – | 464 |
|
|
2017
Q3 | $234K | Buy |
13,300
+300
| +2% | +$5.28K | 0.01% | 414 |
|
|
2017
Q2 | $432K | Buy |
13,000
+800
| +7% | +$26.6K | 0.02% | 327 |
|
|
2017
Q1 | $391K | Buy |
+12,200
| New | +$391K | ﹤0.01% | 261 |
|
|
2015
Q1 | – | Sell |
-19,500
| Closed | -$1.12M | – | 175 |
|
|
2014
Q4 | $1.12M | Buy |
+19,500
| New | +$1.12M | 0.09% | 95 |
|
|
2014
Q3 | – | Sell |
-7,200
| Closed | -$377K | – | 225 |
|
|
2014
Q2 | $377K | Buy |
7,200
+1,300
| +22% | +$68.1K | 0.02% | 127 |
|
|
2014
Q1 | $312K | Sell |
5,900
-37,000
| -86% | -$1.96M | 0.02% | 123 |
|
|
2013
Q4 | $1.72M | Buy |
+42,900
| New | +$1.72M | 0.05% | 90 |
|
|
2013
Q3 | – | Sell |
-62,300
| Closed | -$2.44M | – | 205 |
|
|
2013
Q2 | $2.44M | Buy |
+62,300
| New | +$2.44M | 0.12% | 85 |
|